1. Home
  2. SRPT vs ETV Comparison

SRPT vs ETV Comparison

Compare SRPT & ETV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sarepta Therapeutics Inc. (DE)

SRPT

Sarepta Therapeutics Inc. (DE)

HOLD

Current Price

$16.55

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest

ETV

Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest

HOLD

Current Price

$14.93

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SRPT
ETV
Founded
1980
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
2000
2005

Fundamental Metrics

Financial Performance
Metric
SRPT
ETV
Price
$16.55
$14.93
Analyst Decision
Hold
Analyst Count
29
0
Target Price
$25.85
N/A
AVG Volume (30 Days)
3.0M
134.8K
Earning Date
05-06-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.99
N/A
Revenue
$2,198,237,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$5.48
N/A
Revenue Growth
15.58
N/A
52 Week Low
$14.68
$13.13
52 Week High
$25.32
$15.31

Technical Indicators

Market Signals
Indicator
SRPT
ETV
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
SRPT
ETV

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

About ETV Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest

Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of common stocks, designated segments of which seek to exceed the total return performance of the S&P 500 and the NASDAQ-100.

Share on Social Networks: